arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

AnaptysBio, Inc.

ANAB Health Care Biotechnology: Pharmaceutical Preparations
$56.80
Today
as of Sep 4, 16:45 ET
Last 30 days +9.00% Jul 28 → Sep 04
$51.50 $53.70 $55.90 $58.10 $60.30 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$56.84
High
$58.77
Low
$56.10
Volume
$1M
Avg Vol
$754,798
Mkt Cap
$1.7B
P/E (TTM)
—
Beta
—
52w High
$72.36
52w Low
$11.40
Div Yield
—
Shares Out
$29M

Recent Press Releases & News last 60 days · 2 items

Aug 17 · 15:03 Insider Monkey
GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control
Jul 14 · 14:56 Insider Monkey
What Makes AnaptysBio (ANAB) an Investment Bet?

Overview

52-week range
$11
$72
74% of range
Avg surprise (last 3)
-154.3%
Avg reaction (last 2)
-2.8%
0% positive
Latest IV / EM
90%
EM ±14.1% · $55 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.84$-1.25$-0.66$-0.07$0.52 Actual $-1.18Actual $-1.58Actual $-1.50Actual $-1.41Actual $-1.64Actual $-1.71Actual $-1.14Actual $-1.28Est $-1.30Actual $-1.34Est $-1.50Actual $0.52Actual $-1.84Est $-0.32 SepMarJunSepMarJunSepMar/2025Jun/2025SepMar/2026
Revenue vs Net Income Revenue Net income
$-53M$-20M$14M$47M$80M Jun 24Sep 24Mar 25Jun 25Sep 25Mar 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue May 12, 2026Mar/2026 $-1.84 $-0.32 -475.0% -43.8% -3.4% earnings
Tue Sep 30, 2025Sep 2025 $0.52 — — — — financials
Wed Aug 6, 2025Jun/2025 $-1.34 $-1.50 +10.7% — — earnings
Mon May 5, 2025Mar/2025 $-1.28 $-1.30 +1.5% — -2.2% earnings
Mon Sep 30, 2024Sep 2024 $-1.14 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.71 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.64 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.41 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.50 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.58 — — — — financials
Fri Sep 30, 2022Sep 2022 $-1.18 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Wed Sep 9, 2026Jun/2026OTHER -$0.22-$1.34 +83.6%

Financials

Income statement (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue$26M—$76M$22M$28M—$30M$11M
Cost of revenue————————
Gross profit————————
Operating income$-35M—$35M$-26M$-28M—$-23M$-40M
Net income$-53M—$15M$-39M$-39M—$-33M$-47M
EPS (diluted)$-1.84—$0.52$-1.34$-1.28—$-1.14$-1.71

Balance sheet (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Cash & equivalents$248M$238M$110M$44M$99M$123M$192M$72M
Inventory————————
Total current assets$316M$350M$331M$292M$363M$432M$449M$367M
Total assets$330M$364M$353M$335M$422M$484M$493M$427M
Long-term debt————————
Total liabilities————————
Total equity$13M$37M$-29M$-45M$34M$71M$84M$10M

Implied volatility — last 90 days

61%132%203%275%346% Jun 07 — IV 105% · EM ±14.6%Jun 08 — IV 105% · EM ±13.8%Jun 09 — IV 109% · EM ±13.7%Jun 10 — IV 117% · EM ±13.8%Jun 11 — IV 113% · EM ±12.5%Jun 12 — IV 104% · EM ±10.6%Jun 15 — IV 132% · EM ±9.6%Jun 16 — IV 159% · EM ±9.4%Jun 17 — IV 217% · EM ±9.1%Jun 19 — IV 91% · EM ±20.1%Jun 22 — IV 94% · EM ±19.6%Jun 23 — IV 90% · EM ±18.5%Jun 24 — IV 89% · EM ±17.8%Jun 25 — IV 86% · EM ±16.8%Jun 26 — IV 90% · EM ±17.2%Jun 29 — IV 93% · EM ±16.5%Jun 30 — IV 88% · EM ±15.1%Jul 01 — IV 88% · EM ±14.7%Jul 02 — IV 91% · EM ±14.7%Jul 03 — IV 94% · EM ±14.7%Jul 06 — IV 112% · EM ±15.6%Jul 07 — IV 111% · EM ±14.7%Jul 08 — IV 112% · EM ±14.1%Jul 09 — IV 118% · EM ±14.0%Jul 10 — IV 112% · EM ±12.4%Jul 13 — IV 153% · EM ±12.8%Jul 14 — IV 176% · EM ±12.7%Jul 15 — IV 167% · EM ±9.9%Jul 20 — IV 78% · EM ±18.4%Jul 21 — IV 87% · EM ±20.3%Jul 22 — IV 91% · EM ±20.7%Jul 23 — IV 84% · EM ±18.9%Jul 24 — IV 81% · EM ±17.9%Jul 27 — IV 92% · EM ±19.1%Jul 28 — IV 85% · EM ±17.5%Jul 29 — IV 86% · EM ±17.3%Jul 30 — IV 88% · EM ±17.2%Jul 31 — IV 94% · EM ±17.9%Aug 03 — IV 91% · EM ±16.1%Aug 04 — IV 91% · EM ±15.7%Aug 05 — IV 92% · EM ±15.4%Aug 06 — IV 89% · EM ±14.3%Aug 07 — IV 91% · EM ±14.3%Aug 10 — IV 93% · EM ±12.9%Aug 11 — IV 96% · EM ±12.7%Aug 12 — IV 102% · EM ±12.7%Aug 13 — IV 96% · EM ±11.3%Aug 14 — IV 86% · EM ±9.5%Aug 17 — IV 136% · EM ±11.4%Aug 18 — IV 128% · EM ±9.3%Aug 19 — IV 143% · EM ±8.4%Aug 20 — IV 346% · EM ±14.5%Aug 24 — IV 64% · EM ±13.3%Aug 25 — IV 63% · EM ±12.9%Aug 26 — IV 65% · EM ±12.9%Aug 27 — IV 68% · EM ±13.3%Aug 28 — IV 65% · EM ±12.4%Aug 31 — IV 61% · EM ±10.8%Sep 01 — IV 71% · EM ±12.3%Sep 02 — IV 73% · EM ±12.2%Sep 03 — IV 70% · EM ±11.4%Sep 04 — IV 90% · EM ±14.1%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in